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Tbjective: Cryoablation of pulmonary metastases might be a useful therapy for
onsurgical candidates.
ethods: The procedure was performed after achievement of local anesthesia for
5 tumors in 20 patients (12 male and 8 female patients; mean age, 57 years). The
rimary end point was the safety and feasibility of cryoablation, and the secondary
nd point was tumor control assessed by follow-up dynamic computed tomographic
canning performed every 3 months.
esults: Of the 22 sessions of cryoablation, pneumothorax occurred in 11, hemop-
ysis occurred in 8, and there was 1 case of phrenic nerve palsy. The mean hospital
tay was 2.6 days. There was local recurrence of 7 (20%) tumors in 7 (35%) patients
uring a 9- to 28-month (median, 21 months) follow-up period. One-year survival
ccording to the Kaplan-Meier method was 89.4%.
onclusion: Percutaneous cryoablation therapy for metastatic lung tumors is feasi-
le and minimally invasive, with satisfactory local control.
ryoablation is used to treat hepatocellular carcinoma1 or prostate carcinoma,2
but although Wang and associates3 have reported their experience of more
than 200 cases of percutaneous pulmonary cryoablation during local anes-
hesia without major complications, the feasibility and efficacy of this technique for
ung tumors have not been established.
Experiments in pigs have shown that a 2- or 3-mm-diameter cryoablation probe
an freeze an area (known as an “ice ball”) 2 to 3 cm in diameter and 4 cm in length
fter 2 cycles of freezing and thawing.4 Furthermore, a technique of puncturing
he center of small intrapulmonary nodules under computed tomographic (CT)
uoroscopic guidance has been developed from the experience of CT-guided
ung biopsy.
The surgical approach for small pulmonary metastases is usually a wedge (or
ncomplete) resection, which is considered sufficient for local curability. Good
esults after complete resection of isolated pulmonary metastases from extrathoracic
alignancies have been reported,5 although others report that the extent of resection
oes not affect the prognosis.6 However, because patients with metastatic pulmo-
ary tumors are likely to develop new lesions after treatment, the loss of pulmonary
unction associated with therapy should be minimal.
Therefore we considered that percutaneous cryoablation under CT guidance with
ocal anesthesia as a locally curative treatment for small lung tumors (3 cm in
iameter) should be possible and feasible. Our prospective study was approved by
he institute’s ethical review board.
he Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 5 1007
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G
TSethods
atient Selection
he study group comprised 20 consecutive patients with metastatic
ulmonary tumors at Keio University Hospital from November
002 through February 2004 selected according to the following
riteria: (1) maximum tumor size less than 3 cm in diameter; (2)
ess than 5 metastatic tumors; (3) projected life expectancy of
reater than 1 year; (4) absence of active extrapulmonary metas-
asis; (5) performance status of 0 to 1 on the Eastern Cooperative
ncology Group scale; (6) definite pathologic diagnosis of a
etastatic tumor or obvious clinical features of pulmonary metas-
asis; (7) provision of written informed consent; and (8) normal
oagulability.
The characteristics of the patients and the main reasons for the
hoice of cryoablation as an alternative to surgical resection are
hown in Table 1.
ryoablation Technique
ryoablation was performed after achievement of local anes-
hesia by one thoracic surgeon and one radiologist. Before
eaving the ward, each patient received an intramuscular injec-
ion of atropine sulfate (0.5 mg) and pentazocine (15 mg). In the
T room a 21-gauge guide needle was inserted into the center
f the targeted tumors under fluoroscopic guidance, and when it
as in the optimal position, a stainless-steel sheath for the
ryoprobe, consisting of an inner guiding sheath and an external
heath, was inserted over the needle. The external sheath for a
-mm-diameter cryoprobe (CRYOcare Cryosurgical Unit;
ndo-care, Irvine, Calif) has inner and outer diameters of 2 and
mm, respectively, and for a 3-mm cryoprobe, these are 3 mm
nd 4 mm, respectively. After the inner sheath was removed,
ither a 2- or 3-mm cryoprobe was inserted through the external
heath, which is 180 mm long, equivalent to the length of the
ryoprobe, and therefore the cryoprobe tip was located at the
nd of the sheath (Figure 1). The cryoprobe uses high-pressure
rgon and helium gas for freezing and thawing, respectively, on
he basis of the Joule-Thompson principle. Cryoablation con-
isted of 2 cycles of 5 minutes of freezing followed by thawing
ntil the temperature of the cryoprobe increased to 20°C and
hen a third cycle of 10 minutes of freezing followed by thawing
Figure 2). The air in the lung can interfere with the creation of
he ice ball. When the cryoprobe is inserted into normal pul-
onary parenchyma, initial freezing can make an ice ball of 1
m in diameter only because the air prevents conduction of low
emperatures and there is not enough water in the parenchyma.
owever, after thawing, the massive intra-alveolar hemor-
Abbreviations and Acronyms
CT  computed tomography
PD  progressive disease
PR  partial response
RECIST Response Evaluation Criteria in Solid Tumors
RFA  radiofrequency ablation
SD  stable diseasehage4 excludes the air and results in a larger ice ball that forms p
008 The Journal of Thoracic and Cardiovascular Surgery ● Man the following freezing. Therefore we performed 3 freeze-
haw cycles to make an ice ball of 2.5 to 3.0 cm in diameter. The
- or 3-mm diameter cryoprobe can freeze an area of 2 cm and
cm in diameter, respectively, and 4 cm long after 3 cycles of
reezing and thawing. Therefore for tumors smaller than 2 cm,
nly 1 cryoprobe is usually inserted, and for 2- to 3-cm tumors,
cryoprobes are used to secure a freezing margin.
After the cryoprobe is removed, fibrin glue is infused into the
uter sheath, and when it coagulates, the outer sheath is removed
hile the inner sheath is used to push the coagulated fibrin into the
rack of the cryoprobe. This is done to reduce the risk of bleeding
nd pneumothorax.
It takes 20 to 30 minutes to place a guide needle into the
ptimal position in the targeted tumor, and cryoablation is not
ABLE 1. Characteristics of patients treated with
ryoablation
ge, y (mean [range]) 57 (36-75)
ex (n)
Male 12 (60%)
Female 8 (40%)
revious treatment for pulmonary
metastases
Chemotherapy 8 (40%)
Radiotherapy 2 (10%)
Immunotherapy 1 (5%)
Pulmonary resection 4 (20%)
ain reason for no resection
Refusal of surgical intervention 6 (30%)
Inadequate predicted
postoperative pulmonary
reserve
5 (25%)
Extrapulmonary metastases 8 (40%)
Asthma 1 (5%)
rimary cancer Cases Tumors
Colorectal cancer 6 (30%) 10 (29%)
Lung cancer 5 (25%) 9 (26%)
Hepatic cancer 2 (10%) 5 (14%)
Soft tissue sarcomas 2 (10%) 4 (11%)
Head and neck cancer 2 (10%) 3 (9%)
Uterus cancer 2 (10%) 3 (9%)
Renal cancer 1 (5%) 1 (3%)
o. of metastatic tumors
Solitary 11 (55%)
2 5 (20%)
3 2 (10%)
4 2 (10%)
istribution of metastatic tumors
Unilateral 17 (85%)
Bilateral 3 (15%)
umor size
10 13 (37%)
1120 17 (49%)
2130 5 (14%)erformed until all gauge needles are inserted.
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G
TSvaluation and Statistical Analysis
he primary end point of this study was the early outcome and
easibility of using cryoablation for pulmonary metastatic tumors
maller than 3 cm. The secondary end point was the effect of
ryoablation on radiographically determined tumor control. We
lso evaluated the type and frequency of complications, radio-
raphic evidence of tumor response after cryoablation treatment,
nd overall survival.
Patients underwent a preoperative chest CT scan and a repeat
can on the day after the cryoablation procedure. Follow-up dy-
amic CT chest scans of patients without iodine allergy were
arried out at 1-month and then 3-month intervals. Increase of the
reated lesion size on follow-up CT scan was diagnosed as local
ecurrence. In some cases CT-guided needle biopsy was added to
btain a definite diagnosis. Changes in tumor mass after cryoab-
ation were measured according to the Response Evaluation Cri-
eria in Solid Tumors (RECIST) protocol,7 which is based on
bjective measurements of lesion size before and after treatment.
omplete response means lesion disappearance (scar) or less than
5% of original size. Partial response (PR) means a greater than
0% decrease in the sum of the largest diameter of all targeted
esions. Stable disease (SD) means a less than 30% decrease in the
um of the largest diameter of all targeted lesions. Progressive
isease (PD) means an increase of greater than 20% in the sum of
he largest diameter of all targeted lesions. Change in each tumor
ize is also important for evaluating the efficacy of cryoablation
ecause patients with metastatic lung tumors usually have multiple
etastatic lesions. Therefore change in each tumor was evaluated
ith the same protocol as RECIST. Because cryoablation can
ause scar formation during the healing process, the lesion size
fter treatment alone does not necessarily reflect treatment effi-
acy. Therefore in addition to RECIST, clinical outcome according
o the follow-up CT scan after more than 1 year can be noted.
The Kaplan-Meier method was used to analyze cumulative
igure 1. Two cryoprobes are inserted under computed tomo-
raphic (CT) guidance. CT scans can be taken as needed during
he cryoablation procedure.urvival after the initial cryoablation. 5
The Journal of Thoracicesults
total 35 pulmonary tumors in 20 patients (12 male and 8
emale patients; mean age, 57 years; age range, 36-75 years)
ere treated with cryoablation. Eastern Cooperative Oncol-
gy Group performance status was 0 in 19 patients and 1 in
patient. In all cases cryoablation was performed percuta-
eously under CT guidance with local anesthesia without
ny major complications. None of the patients had major
omplications associated with the procedure. The pulmo-
ary metastases were from colorectal cancer (n  6), pre-
iously resected non–small cell lung cancer (n  5), head
nd neck cancer (n  2), soft tissue sarcoma (n  2),
epatic cancer (n  2), uterine cancer (n  2), and renal
ancer (n  1). The number of metastases was 1 in 11
atients, 2 in 5 patients, 3 in 2 patients, and 4 in 2 patients;
patients had bilateral metastases, and of them, 2 under-
ent cryoablation twice with an interval of 1 to 2 months,
nd the other patient underwent simultaneous cryoablation
or the metastases. Therefore a total of 22 sessions of
ryoablation were performed. The size of the treated lesions
as 6 to 10 mm in 13 tumors, 11 to 20 mm in 17 tumors,
nd 21 to 30 mm in 5 tumors (mean tumor size, 13.3 mm).
The main reasons why those patients underwent cryoa-
lation instead of surgical intervention were refusal of sur-
ical intervention in 6 patients, inadequate predicted post-
perative pulmonary reserve in 5 patients, extrapulmonary
etastases in 8 patients, and asthma in 1 patient (Table 1).
Pneumothorax occurred in 11 of the 22 sessions, primar-
ly after the completion of the ablation procedure. A chest
ube was inserted in 1 case, transient needle aspiration was
erformed in 3 cases, and in 7 cases no additional treatment
as given. In 7 cases a small amount of pleural effusion was
etected on a chest CT scan carried out on postoperative day
, but no additional treatment was required. Pleural dissem-
nation was detected during the follow-up period in 1 patient
hose postoperative CT scans did not show any pleural
ffusion. Because there had been multiple pulmonary me-
astases on the lung surface, it is unclear whether the cryoa-
lation induced pleural dissemination. Hemoptysis occurred
uring 8 sessions and subsided in a few days in all patients.
here was no apparent correlation between tumor location
nd the incidence of hemoptysis. Phrenic nerve palsy oc-
urred during 1 session for a tumor located near the left
hrenic nerve and had not improved when the patient died
f brain metastases 9 months later (Table 2).
Mean hospital stay after treatment was 2.6 days (range,
-9 days), although for the initial 5 sessions, it was 5.4 days.
here were no treatment-related deaths or conversion to
urgical intervention.
The response to cryoablation according to RECIST was
omplete response in 2 patients, PR in 8 patients, SD in 8
atients, and PD in 2 patients, giving a response rate of
0%. In 3 of 8 patients with PR and 2 of 8 patients with SD,
and Cardiovascular Surgery ● Volume 131, Number 5 1009
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1
G
TShere was tumor recurrence. The response of each tumor
as complete in 8 patients, partial in 11 patients, SD in 14
atients, and PD in 2 patients, giving a response rate of
4.3%.
One patient died of brain metastases 9 months after
ryoablation, and another patient died of bone and kidney
etastases 10 months later, but neither had pulmonary local
ecurrence. The remaining 18 patients survived more than 1
ear. The follow-up period was 9 to 28 months (median, 21
onths), and in the 9 to 12 months after cryoablation, there
as local recurrence of 7 (20%) tumors (median time to
rogression of 9 months) in 7 (35%) patients: 5 patients
nderwent repeat cryoablation without complications, 1 pa-
ients initially refused surgical intervention and underwent
urgical resection, and 1 patients was given chemotherapy
Figure 2. Sequential changes of the pulmonary parench
thawing. 1, The metastatic tumor is located in right S4.
the beginning of first freezing, the change of surroundi
along the cryoprobe can be seen. 5, Five minutes a
consolidated area can be seen. 6, After third thawing.or both the recurrent and new lesions. There was 1 case of C
010 The Journal of Thoracic and Cardiovascular Surgery ● Mauspected subcutaneous recurrence along the insertion
rack, which was surgically resected. To date, there have
een no cases of local recurrence after repeat cryoablation
(Table 3).
on computed tomographic scanning after freezing and
e cryoprobe penetrates the tumor. 3, Five minutes after
ng is quite small. 4, After first thawing, consolidation
the beginning of second freezing, extension of the
ABLE 2. Complications after cryoablation
omplication No. %
neumothorax 11 50
Chest tube 1 4.5
Manual aspiration 3 13.5
Course observation 7 32
leural effusion 6 27
emosputum 9 41
hrenic nerve palsy 1 4.5yma
2, Th
ng lu
fterhest wall implantation 1 4.5
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G
TSThe 1-year survival rate after the initial cryoablation
herapy for metastatic pulmonary tumors was 89.4%, as
etermined by using the Kaplan-Meier method (Figure 3).
iscussion
urgical intervention is the usual option for local cure of
etastatic pulmonary cancer, and wedge resection, which
reserves residual pulmonary function better than radical
obectomy with mediastinal lymph node dissection, results
n local curability to some extent. According to the Inter-
ABLE 3. Radiographic response and clinical result
atient no. Primary tumor
Nodules treated
with cryoablation REC
1 Synovial sarcoma 1 CR
2 NSCLC 2 PR
3 NSCLC 1 PR¡
4 Colon cancer 1 SD
5 Head and neck cancer 1 SD
6 Colon cancer 1 PD
7 Colon cancer 4 SD¡
8 Lung cancer 1 PR¡
9 Colon cancer 1 SD
10 Hepatic cancer 4 PR
11 NSCLC 2 PR
12 Head and neck 2 SD¡
13 NSCLC 3 PR¡
14 Neurofibrosarcoma 3 CR
15 Hepatic cancer 1 SD
16 Colon cancer 2 PR
17 Renal cancer 1 PR
18 Uterus cancer 1 PD
19 Colon cancer 1 SD
20 Uterine cancer 2 SD
ECIST, Response Evaluation Criteria in Solid Tumors; CR, complete re
R, partial response; SD, stable disease; PD, progressive disease.ational Registry of Lung Metastases,5 the 5-year survival e
The Journal of Thoracicate after incomplete resection for a metastatic lung tumor is
3% and 36% after complete resection, which suggests that
urgical treatment might contribute to survival. However,
ome patients with advanced cancer might not tolerate sur-
ical resection. Hence if equally effective, a less invasive
herapy is preferable. This is why we evaluated the local
urability, as well as the feasibility, of cryoablation. Al-
hough cryoablation has been performed for hepatic1 or
rostate2 cancer and achieved acceptable results, in most
ases it has been performed after achievement of general or
Each tumor’s
response
Clinical outcome (prognosis after initial
cryoablation)
CR New pulmonary lesions (18 POM
dead)
PR, SD Disease free (27 POM alive)
PR¡PD Recryoablation for local recurrence
(26 POM alive with new
pulmonary lesions)
SD New pulmonary lesions (25 POM
alive)
SD New pulmonary lesions (24 POM
alive)
PD Recryoablation for local recurrence
(18 POM alive with new
pulmonary lesions)
PR, SD, SD, SD¡PD Surgical resection for local
recurrence (21 POM disease free)
PR¡PD Recryoablation for local recurrence
(21 POM disease free)
SD Surgical resection for subcutaneous
implantation (21 POM alive with
new pulmonary lesions)
PR, SD, SD, CR New metastatic lesions (19 POM
alive)
PR, PR Brain metastasis (9 POM dead)
CR, SD¡PD Recryoablation for local recurrence
(18 POM disease free)
CR, PR, SD¡PD Chemotherapy for local recurrence
and new lesions (18 POM alive)
CR, CR, CR New metastatic lesions (18 POM
alive)
SD Disease free (16 POM alive)
CR, PR Bone and kidney metastases
(10 POM dead)
PR Disease free (14 POM alive)
PD Recryoablation for local recurrence
(14 POM disease free)
SD New metastatic lesions (14 POM
alive)
PR, SD Disease free (12 POM alive)
se; POM, post operative months; NSCLC, non–small cell lung cancer;IST
PD
PD
PD
PD
PD
sponpidural anesthesia. In our clinical study all the procedures
and Cardiovascular Surgery ● Volume 131, Number 5 1011
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1
G
TSere performed after administration of local anesthesia
nly, which is similar to the conditions in the study by
ang and colleagues.3 Moorjani and associates8 reported
he effect of cryoanalgesia on the intercostal nerves, and
rom the viewpoint of treatment-associated pain, cryoabla-
ion seems an ideal technique. However, some patients
omplained of dull pain in the anterior chest after treatment,
hich we suspect was related to freezing of the intercostal
erves, and it usually disappeared within a few months.
One patient required a chest tube for pneumothorax, but
or the other 10 cases of a small amount of air leakage,
ransient manual aspiration was sufficient to control it. He-
othorax requiring chest tube drainage did not occur. Izumi
nd coworkers9 observed from animal experiments that the
oagulated blood surrounding the outer sheath apparently
revents massive air leakage and bleeding in the damaged
ulmonary tract. The patient with the chest tube remained in
he hospital for 9 days after treatment, but the average
ospital stay was 2.6 days, which is shorter than the 4.5 days
fter video-assisted wedge resection at the same hospital.
As for other complications, hemoptysis occurred in 50%
f sessions. In animal experiments rupture of the capillary
all and hemorrhage in the alveolar space were observed
icroscopically in the frozen area after thawing.4 We sup-
ose this phenomenon is a kind of hemorrhagic pulmonary
dema caused by the death of endothelial cells. Therefore
emoptysis seems inevitable after pulmonary cryoablation
nd is not a serious condition because it is caused by the
upture of capillaries rather than large vessels. Actually,
emoptysis was not usually associated with shortness of
reath.
There are some reports on the use of radiofrequency
blation (RFA) for pulmonary malignancies.10-13 The RFA
igure 3. Accumulated survival curve by means of the Kaplan-
eier method.evices are more compact and cheaper than those for cryoa- (
012 The Journal of Thoracic and Cardiovascular Surgery ● Malation. It was reported that in RFA 1 retreated patient with
etastatic disease died of massive hemoptysis 21 days after
pen RFA of a central nodule.10 Because the patient had
lso undergone brachytherapy 4 days prior, the cause of the
stula between the bronchus and the large pulmonary vessel
as unclear; however, the authors state that they have ceased
sing RFA for central nodules since that complication.
We used cryoablation for centrally located tumors in 3
ases without any major complications (Figure 4), although
he number of patients in this study is small. We know that
he bronchial wall can resist temperatures of 120°C to
130°C because tracheas obtained from cadavers for trans-
lantation can be deep-frozen.14,15 Some reports suggest
hat the collagenous architecture of the central bronchi and
asculature is preserved by endobronchial cryotherapy.16-18
n the other hand, the wall of large blood vessels heated by
irculating blood during cryoablation seems to preserve the
essel wall structure.
Because metastatic lung tumors are expected to poten-
ially associate with the other latent metastatic lesions in the
ung, pulmonary reserve after treatment seems important.
hen cryoablation can be applied to centrally located tu-
ors, greater pulmonary reserve is expected after cryoab-
ation than after a surgical procedure such as lobectomy,
hich is usually required for the resection of those tumors
igure 4. Cryoprobe can approach to the hilar lesions. A case
ith 6 peripheral and 1 central metastases: 6 peripheral metas-
ases had been resected surgically. A centrally located tumor is
hown in a 3-dimensional computed tomographic image. Two
ryoprobes are inserted into the lung. Because the tumor was
ocated close to a large vessel, 2 probes are inserted almost
arallel, like chopsticks, so as to encase the tumor. This avoids
essel and airway damage, and preserves pulmonary function.Figure 4).
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G
TSFor tumors larger than 2.0 cm in diameter, 2 or more
ryoprobes are usually inserted around the tumor, but in those
ases, the ice ball is irregular in shape, and it is difficult to
ccurately assess the positional relationship of the tumor and
ce ball on CT images, although 3-dimensional CT should
elp. However, more basic research is required, and we do not
se cryoablation for tumors larger than 3.0 cm in diameter.
evertheless, there was local recurrence of approximately
0% of the ablated tumors and further improvements in the
echnique, and the CT images are necessary to decrease this
ate. Of course, another cause of local recurrence after
ryoablation is that the metastatic tumor might have satellite
esions or there is microinvasion into the lymph ducts, and
ocal treatment, such as cryoablation or wedge resection,
as the limitation to curative local control of metastatic lung
umors.
The response of the tumors was evaluated according to
ECIST, and even though the marked scar formation
round the tumor after cryoablation would seem to make
ccurate evaluation of tumor size on CT images impossible,
f the 11 of 14 tumors diagnosed as SD by RECIST, local
ecurrence has not occurred during follow-up of more than
4 months. Long-term follow-up with CT scanning period-
cally is thought to be the most appropriate way to evaluate
ocal control of tumors after cryoablation. Positron emission
omography might also be very useful to evaluate local control,
lthough we have not done this in the present study. Because
ll cases of recurrence occurred 6 to 12 months (median, 9
onths) after cryoablation, particular attention must be given
o this period, especially for the common metastatic lung
umors, although longer observation of low-grade malignant
umor is necessary. A larger multi-institutional study would be
deal to further evaluate feasibility, but we need to collect
ore data before such studies can be designed. We also
eed to train individuals to gain better recognition of this
echnique. At our institution, we start by training the tech-
iques necessary for CT-guided biopsy.
onclusion
ercutaneous cryoablation therapy for metastatic lung tu-
ors was feasible and minimally invasive, with satisfactory
ocal control. This technique could also be used without any
erious complications for tumors located near the hilar pulmo-
ary vessels. However, the number of patients enrolled in this
tudy was small, and thus the efficacy of cryoablation for the
reatment of metastatic lung cancer is still unclear. A larger
hase II study comparing cryoablation with wedge resection,
tereotactic radiotherapy, or RFA therapy is necessary to 1
The Journal of Thoracicetermine its efficacy and role in the local control of met-
static lung tumors. Overall, we consider that with further
tudies and more accurate estimation of the ablated volume,
ventually in selected cases cryoablation might not be in-
erior to wedge resection for the local control of metastatic
ung tumors.
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